Literature DB >> 32313112

Oral ADT demonstrates greater efficacy than existing injectable treatment.

Tim Thomas1.   

Abstract

Entities:  

Year:  2020        PMID： 32313112     DOI： 10.1038/s41585-020-0322-z

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.

Authors:  David P Dearnaley; Daniel R Saltzstein; John E Sylvester; Lawrence Karsh; Bryan A Mehlhaff; Christopher Pieczonka; James L Bailen; Hongliang Shi; Zhan Ye; Hélène M Faessel; Huamao Lin; Yanyan Zhu; Fred Saad; David B MacLean; Neal D Shore
Journal:  Eur Urol       Date:  2020-04-06       Impact factor: 20.096
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.